Would you add bevacizumab to osimertinib for a patient with NSCLC who is progressing on osimertinib with no other actionable resistance mutations?  

This is a good question. This likely stems from the fact there are studies that show the combination of erlotinib with bevacizumab is associated with improved PFS, compared to single agent erlotinib in the first line setting. The combination of osimertinib, a superior EGFR TKI, to bevacizumab is bei...

I would certainly consider this option.